PMPiyushkumar A. Mundra

Piyushkumar A. Mundra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Piyushkumar A. Mundra has a total of 305 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modality-aware external attention with explicit cross-omics interaction modelling for breast cancer subtype classification

    by Deepali Pilodiya, Madhu Chetty, Azadeh Noori Hoshyar, Piyushkumar A. Mundra, Cameron Foale

  • Open Access

    Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans

    by Michael R. Sargen, Jung Kim, Jeremy S. Haley, Hayley P. Barker, Piyushkumar A. Mundra, Mandy L. Ballinger, David M. Thomas, David J. Carey, Alisa M. Goldstein, Douglas R. Stewart


  • Heritable defects in telomere and mitotic function selectively predispose to sarcomas

    by Mandy L. Ballinger, Swetansu Pattnaik, Piyushkumar A. Mundra, Milita Zaheed, Emma Rath, Peter Priestley, Jonathan Baber, Isabelle Ray-Coquard, Nicholas Isambert, Sylvain Causeret, et al.

    Cancer genetics has to date focused on epithelial malignancies, identifying multiple histotype-specific pathways underlying cancer susceptibility. Sarcomas are rare malignancies predominantly derived from embryonic mesoderm. To identify pathways specific to mesenchymal cancers, we performed whole-genome germline sequencing on 1644 sporadic cases and 3205 matched healthy elderly controls. Using an extreme phenotype design, a combined rare-variant burden and ontologic analysis identified two sarcoma-specific pathways involved in mitotic and telomere functions. Variants in centrosome genes are linked to malignant peripheral nerve sheath and gastrointestinal stromal tumors, whereas heritable defects in the shelterin complex link susceptibility to sarcoma, melanoma, and thyroid cancers. These studies indicate a specific role for heritable defects in mitotic and telomere biology in risk of sarcomas.


  • Open Access

    PIKE-R2P: Protein–protein interaction network-based knowledge embedding with graph neural network for single-cell RNA to protein prediction

    by Xinnan Dai, Fan Xu, Shike Wang, Piyushkumar A. Mundra, Jie Zheng

    Background: Recent advances in simultaneous measurement of RNA and protein abundances at single-cell level provide a unique opportunity to predict protein abundance from scRNA-seq data using machine learning models. However, existing machine learning methods have not considered relationship among the proteins sufficiently. Results: We formulate this task in a multi-label prediction framework where multiple proteins are linked to each other at the single-cell level. Then, we propose a novel method for single-cell RNA to protein prediction named PIKE-R2P, which incorporates protein–protein interactions (PPI) and prior knowledge embedding into a graph neural network. Compared with existing methods, PIKE-R2P could significantly improve prediction performance in terms of smaller errors and higher correlations with the gold standard measurements. Conclusion: The superior performance of PIKE-R2P indicates that adding the prior knowledge of PPI to graph neural networks can be a powerful strategy for cross-modality prediction of protein abundances at the single-cell level.


  • Open Access

    Ultraviolet radiation drives mutations in a subset of mucosal melanomas

    by Piyushkumar A. Mundra, Nathalie Dhomen, Manuel Rodrigues, Lauge Hjorth Mikkelsen, Nathalie Cassoux, Kelly Brooks, Sara Valpione, Jorge S. Reis-Filho, Steffen Heegaard, Marc-Henri Stern, et al.

    Although identified as the key environmental driver of common cutaneous melanoma, the role of ultraviolet radiation (UVR)-induced DNA damage in mucosal melanoma is poorly defined. We analyze 10 mucosal melanomas of conjunctival origin by whole genome sequencing and our data shows a predominance of UVR-associated single base substitution signature 7 (SBS7) in the majority of the samples. Our data shows mucosal melanomas with SBS7 dominance have similar genomic patterns to cutaneous melanomas and therefore this subset should not be excluded from treatments currently used for common cutaneous melanoma.


  • Map3k1 Loss Cooperates with Braf to Drive Melanomagenesis

    by Lucas D. Trucco, Piyushkumar A. Mundra, Pablo García-Martínez, Kate Hogan, Franziska Baenke, Nathalie Dhomen, Valeria Pavet, Richard Marais


  • Open Access

    Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

    by Elena Galvani, Piyushkumar A. Mundra, Sara Valpione, Pablo Garcia-Martinez, Matthew Smith, Jonathan Greenall, Rohit Thakur, Beth Helmink, Miles C. Andrews, Louis Boon, et al.

    Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatment with programmed cell death-1 (PD-1) blockade in a genetically engineered mouse model of melanoma driven by oncogenic BRAF. In this controlled system anti-PD-1 treatment yields responses in ~35% of the tumors, and prolongs survival in ~27% of the animals. We identify increased stroma remodeling and reduced expression of proliferation markers as features associated with prolonged response. These traits are corroborated in two independent early on-treatment anti-PD-1 melanoma patient cohorts. These insights into the biological responses of tumors to ICI provide a strategy for identification of durable response early during the course of treatment and could improve patient stratification for checkpoint inhibitory drugs.


  • Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

    by Sara Valpione, Elena Galvani, Joshua Tweedy, Piyushkumar A. Mundra, Antonia Banyard, Philippa Middlehurst, Jeff Barry, Sarah Mills, Zena Salih, John Weightman, et al.

    Our understanding of how checkpoint inhibitors (CPIs) affect T cell evolution is incomplete, limiting our ability to achieve full clinical benefit from these drugs. Here, we analyzed peripheral T cell populations after one cycle of CPI treatment and identified a dynamic awakening of the immune system, as revealed by T cell evolution in response to treatment. We sequenced T cell receptors in plasma cell-free DNA and peripheral blood mononuclear cells and performed phenotypic analysis of peripheral T cell subsets from patients with metastatic melanoma treated with CPIs. We found that early peripheral T cell turnover and T cell receptor repertoire dynamics identified which patients would respond to treatment. Additionally, the expansion of a subset of immune effector peripheral T cells we call TIE cells correlated with response. These events are prognostic and occur within 3 weeks of starting immunotherapy, raising the potential for monitoring patients’ responses by using minimally invasive liquid biopsies.


  • Open Access

    Changes in plasma lipids predict pravastatin efficacy in secondary prevention

    by Kaushala S. Jayawardana, Piyushkumar A. Mundra, Corey Giles, Christopher K. Barlow, Paul J. Nestel, Elizabeth H. Barnes, Adrienne Kirby, Peter Thompson, David R. Sullivan, Zahir H. Alshehry, et al.

    BACKGROUND: Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS: Plasma lipids ( n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort ( n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR). RESULTS: Pravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile. CONCLUSION: The change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier ACTRN12616000535471. FUNDING: Bristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.


  • Publisher Correction: Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma

    by Lucas D. Trucco, Piyushkumar A. Mundra, Kate Hogan, Pablo Garcia-Martinez, Amaya Viros, Amit K. Mandal, Nicolas Macagno, Caroline Gaudy-Marqueste, Donald Allan, Franziska Baenke, et al.

    In the version of this article originally published, Extended Data Fig. 3 was incorrect. A duplicate of Extended Data Fig. 4 was uploaded in place of Extended Data Fig. 3. Extended Data Fig. 3 has now been uploaded. The error has been fixed in the PDF and HTML versions of this article.